Related Experiment Video

Updated: Aug 17, 2026

Network Pharmacology and Validation of the Antidepressant Mechanisms of Qiangzhifang in a Chronic Restraint Stress-induced Depression Rat Model
08:15

Network Pharmacology and Validation of the Antidepressant Mechanisms of Qiangzhifang in a Chronic Restraint Stress-induced Depression Rat Model

Published on: June 6, 2025

Pharmacologic treatment of depression in patients with heart disease

Steven P Roose1, Marissa Miyazaki

  • 1College of Physicians and Surgeons, Columbia University, New York, New York, USA. spr2@columbia.edu

Psychosomatic Medicine
|June 15, 2005
PubMed

Insights

Treating depression in patients with heart disease is crucial. Selective serotonin reuptake inhibitors (SSRIs) show promise as safe and effective options for managing depression and improving cardiac outcomes.

Area of Science:

  • Cardiology
  • Psychiatry
  • Pharmacology

Background:

  • Depression is linked to adverse cardiovascular outcomes, including increased mortality post-myocardial infarction.
  • The interplay between depression and cardiovascular disease (CVD) necessitates understanding treatment efficacy and safety.

Purpose of the Study:

  • To evaluate the safety and effectiveness of antidepressant treatments in patients with comorbid depression and ischemic heart disease (IHD).
  • To determine if treating depression reduces cardiac morbidity and mortality in patients with IHD.

Main Methods:

  • Review of existing data, primarily from open or comparator trials, on tricyclic antidepressants (TCAs) and selective serotonin reuptake inhibitors (SSRIs).
  • Analysis of response rates and cardiovascular safety profiles of TCAs and SSRIs in patients with IHD.

Main Results:

  • Both TCAs and SSRIs demonstrate effectiveness in treating depression among patients with IHD, with comparable response rates to those without heart disease.
  • TCAs are associated with significant adverse cardiovascular effects, including increased heart rate, orthostatic hypotension, and conduction delays, posing risks for IHD patients.
  • SSRIs appear to be relatively safe and effective for treating depression in patients with comorbid IHD.

Conclusions:

  • Selective serotonin reuptake inhibitors (SSRIs) are a relatively safe and effective treatment option for depression in patients with ischemic heart disease (IHD).
  • Tricyclic antidepressants (TCAs) carry a proven increased risk of cardiac morbidity and mortality in patients with IHD and should be used with caution.
  • Further research is needed to fully elucidate the benefits of depression treatment on cardiac outcomes in patients with comorbid conditions.

More Related Videos

Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression04:29

Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression

Published on: January 7, 2019

Related Concept Videos

Antidepressant Drugs: MAOIs and Other Agents01:23

Antidepressant Drugs: MAOIs and Other Agents

Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
Antidepressant Drugs: Overview01:25

Antidepressant Drugs: Overview

Antidepressant drugs are a class of medications primarily used for treating various mood disorders, including major depression, anxiety disorders, and other related conditions. These medicines work by modulating the neurotransmitter balance within the brain, alleviating depressive symptoms. Antidepressants can be broadly categorized into several groups according to their mechanism of action and chemical structure: Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin-Norepinephrine...
Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs01:28

Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs

Tricyclic Antidepressants (TCAs), including Desipramine (Norpramin), Imipramine (Tofranil), Clomipramine (Anafranil), and Amitriptyline (Elavil), inhibit serotonin and norepinephrine reuptake and also block other receptors. They are used for depression, pain conditions, and insomnia. Common adverse effects include anticholinergic effects, sedation, orthostatic hypotension, and weight gain. They have a narrow therapeutic window and so require plasma-level monitoring. Abrupt discontinuation can...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...